Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (313)	5/20/1999 7:41:00 PM
From: Miljenko Zuanic	Read Replies (1) of 804

Peter, I know that FDA is sitting on their shoulder and watching every move. I am not recommending that they hype T, but few more words (I think that Sinai and Australian abstract, plus two more from Boston and UK speak for itself) in PR will not piss-off FDA. But it did make me angry. 12 or 10 pts T results for IBD are small numbers for very serious consideration by MDs, but combined with other T trials for inflammatory conditions (overall ~30 trials ongoing or completed) mount to significant clinical data which can help MDs to develop proper practice : when, why and how to proscribed T. Nonetheless, the point is here that small molecules as cytokine modulators can be as effective as Ramicade or Embrel. Market is hungry for this type of drug. So, JJ, what is holding you? If CELG do not have sufficient medical and financial (I think that they do not have) condition to speed-up development of T, SelCIDs and IMIDs, appropriate partner will have! Others are not sleeping and competition will grow faster than anyone expect! Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next